ORCHPHARMAPharmaceuticals
Orchid Pharma Ltd — Profit & Loss Statement
₹482.45
-5.52%
Orchid Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.30 | 0.30 | 0.00 | 0.00 | — |
| Normalized EBITDA | 144.65 Cr | 141.54 Cr | 102.26 Cr | 61.62 Cr | — |
| Total Unusual Items | 0.00 | -0.65 Cr | 40.00 Cr | 0.51 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | -0.65 Cr | 40.00 Cr | 0.51 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 99.66 Cr | 92.17 Cr | 53.09 Cr | -60.42 Cr | — |
| Reconciled Depreciation | 34.55 Cr | 33.24 Cr | 54.79 Cr | 87.02 Cr | — |
| Reconciled Cost Of Revenue | 544.22 Cr | 484.46 Cr | 397.18 Cr | 326.29 Cr | — |
| EBITDA | 144.65 Cr | 141.54 Cr | 142.26 Cr | 62.14 Cr | — |
| EBIT | 110.10 Cr | 108.30 Cr | 87.47 Cr | -24.89 Cr | — |
| Net Interest Income | -14.54 Cr | -16.35 Cr | -32.28 Cr | -33.04 Cr | — |
| Interest Expense | 14.54 Cr | 16.35 Cr | 32.23 Cr | 32.01 Cr | — |
| Normalized Income | 99.66 Cr | 92.17 Cr | 13.09 Cr | -60.93 Cr | — |
| Net Income From Continuing And Discontinued Operation | 99.66 Cr | 92.17 Cr | 46.32 Cr | -1.95 Cr | — |
| Total Expenses | 665.13 Cr | 587.34 Cr | 636.23 Cr | 592.00 Cr | — |
| Diluted Average Shares | 5.07 Cr | 4.84 Cr | 4.08 Cr | 4.08 Cr | — |
| Basic Average Shares | 5.07 Cr | 4.84 Cr | 4.08 Cr | 4.08 Cr | — |
| Diluted EPS | 19.65 | 19.06 | 11.35 | -0.48 | — |
| Basic EPS | 19.65 | 19.06 | 11.35 | -0.48 | — |
| Diluted NI Availto Com Stockholders | 99.66 Cr | 92.17 Cr | 46.32 Cr | -1.95 Cr | — |
| Net Income Common Stockholders | 99.66 Cr | 92.17 Cr | 46.32 Cr | -1.95 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 99.66 Cr | 92.17 Cr | 46.32 Cr | -1.95 Cr | — |
| Net Income Including Noncontrolling Interests | 99.66 Cr | 92.17 Cr | 46.32 Cr | -1.95 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | -6.78 Cr | 58.47 Cr | — |
| Net Income Continuous Operations | 99.66 Cr | 92.17 Cr | 53.09 Cr | -60.42 Cr | — |
| Tax Provision | -0.19 Cr | -3.12 Cr | 0.00 | 0.00 | — |
| Pretax Income | 95.56 Cr | 91.95 Cr | 55.25 Cr | -56.90 Cr | — |
| Other Non Operating Income Expenses | -146.69 Cr | -123.73 Cr | 12.66 Cr | 0.49 Cr | — |
| Special Income Charges | 0.00 | -0.65 Cr | 39.98 Cr | 4000.00 | — |
| Net Non Operating Interest Income Expense | -14.54 Cr | -16.35 Cr | -32.28 Cr | -33.04 Cr | — |
| Interest Expense Non Operating | 14.54 Cr | 16.35 Cr | 32.23 Cr | 32.01 Cr | — |
| Operating Income | 256.80 Cr | 232.03 Cr | 29.67 Cr | -32.45 Cr | — |
| Operating Expense | 120.91 Cr | 102.88 Cr | 239.05 Cr | 265.72 Cr | — |
| Depreciation And Amortization In Income Statement | 34.55 Cr | 33.24 Cr | 54.79 Cr | 87.02 Cr | — |
| Depreciation Income Statement | 34.55 Cr | 33.24 Cr | 54.78 Cr | 86.99 Cr | — |
| Gross Profit | 377.70 Cr | 334.91 Cr | 268.72 Cr | 233.27 Cr | — |
| Cost Of Revenue | 544.22 Cr | 484.46 Cr | 397.18 Cr | 326.29 Cr | — |
| Total Revenue | 921.93 Cr | 819.37 Cr | 665.90 Cr | 559.56 Cr | — |
| Operating Revenue | 921.93 Cr | 819.37 Cr | 665.90 Cr | 559.56 Cr | — |
| Interest Income | — | 16.35 Cr | 0.62 Cr | 0.42 Cr | 0.73 Cr |
| Rent Expense Supplemental | — | 3.34 Cr | 1.02 Cr | 1.58 Cr | 1.51 Cr |
| Other Special Charges | — | 0.19 Cr | -39.98 Cr | -4000.00 | 0.07 Cr |
| Write Off | — | 0.46 Cr | 0.00 | — | — |
| Total Other Finance Cost | — | 0.38 Cr | 0.68 Cr | 1.44 Cr | 0.87 Cr |
| Interest Income Non Operating | — | 16.35 Cr | 0.62 Cr | 0.42 Cr | 0.73 Cr |
| Other Operating Expenses | — | 89.85 Cr | 85.97 Cr | 74.74 Cr | 49.87 Cr |
| Amortization | — | 1.13 Cr | 78000.00 | 0.03 Cr | 0.03 Cr |
| Research And Development | — | 7.09 Cr | 6.36 Cr | 6.63 Cr | 4.81 Cr |
| Selling General And Administration | — | 32.28 Cr | 23.12 Cr | 30.90 Cr | 26.35 Cr |
| Selling And Marketing Expense | — | 23.86 Cr | 14.34 Cr | 22.26 Cr | 13.46 Cr |
| General And Administrative Expense | — | 8.43 Cr | 8.79 Cr | 8.64 Cr | 12.90 Cr |
| Rent And Landing Fees | — | 3.34 Cr | 1.02 Cr | 1.58 Cr | 1.51 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Orchid Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.